



PATENT CASE IN01159K

IDS / 1653
#3
1/8/02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

A. Saksena *et al.*

Serial No.: 09/908,955

Filed: July 19, 2001

)
) Examiner: Not assigned yet
)
) Group Art Unit: Not assigned yet
)
) Atty. Docket No.: IN01159K

For: **NOVEL PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF
HEPATITIS C VIRUS**

Assistant Commissioner for Patents
Washington, D.C. 20231

RECEIVED
JAN 14 2002
TECH CENTER 1600/2900

INFORMATION DISCLOSURE STATEMENT

Sir:

It is requested that the following documents cited in the application, as listed below and in the accompanying form PTO-1449, be considered and made of record.

Documents cited in the Application:

U.S. 5,712,145
WO 89/04669
WO 98/17679
WO 98/22496
WO 99/07734
WO 00/09558
WO 00/09543
EP 381 216

Publications:

Pizzi *et al.* (1994) *Proc. Natl. Acad. Sci (USA)* 91:888-892
Failla *et al.* (1996) *Folding & Design* 1:35-42
Kollykhalov *et al.* (1994) *J. Virol.* 68:7525-7533
Komoda *et al.* (1994) *J. Virol.* 68:7351-7357
Landro *et al.* (1997) *Biochem.* 36:9340-9348
Ingallinella *et al.* (1998) *Biochem.* 37:8906-8914
Llinàs-Brunet *et al.* (1998) *Bioorg. Med. Chem. Lett.* 8:1713-1718
Martin *et al.* (1998) *Biochem.* 37:11459-11468
Dimasi *et al.* (1997) *J. Virol.* 71:7461-7469
Martin *et al.* (1997) *Protein Eng.* 10:607-614
Elzouki *et al.* (1997) *J. Hepat.* 27:42-48
BioWorld Today 9(217): 4 (November 10, 1998)
Berenguer *et al.* (1998) *Proc. Assoc. Am. Physicians* 110(2):98-112
Hoofnagle *et al.* (1997) *N. Engl. J. Med.* 336:347
R. Zhang *et al.*, *Analytical Biochemistry*, 270 (1999) 268-275

D. L. Sali *et al*, *Biochemistry*, 37 (1998) 3392-3401
K. Barlos *et al*, *Int. J. Pept. Protein Res.*, 37 (1991), 513-520
K. Holmberg *et al*, *Acta Chem. Scand.*, B33 (1979) 410-412
A. Marchetti *et al*, *Synlett.*, S1 (1999) 1000-1002
W. Han *et al*, *Bioorganic & Biomedical Chem Lett.*, 10 (2000) 711-713
S. Agrawal *et al*, "Development and Characterization of Hepatitis C Virus Serine
Protease Cell-based Trans-Cleavage Assay", *Hepatology* Supplement to Volume 30 (No. 4,
Part 2, October 1999), *Abstract No. 615* (Proceedings of AASLD 50th Annual Meeting,
Dallas, Texas, November 5-9, 1999.
L. Hughes, *Org. Reactions*, 42 (1992) 335.
R. F. Heck, *Org. Reactions*, 27 (1989) 345-390.

The submission of these documents is not to be presumed as an admission that these documents are prior art. The documents are being furnished solely for their possible utility in the examination of the present case. Since no Office Action has issued on the merits of this case, Applicants believe that no fee is due at this time. If, however, any fees are due, the Office may charge such fees to Deposit Account No. 19-0365.

If the Examiner has any questions, the Examiner is invited to contact the undersigned.

December 19, 2001
Schering-Plough Corporation
2000 Galloping Hill Road
Patent Department, K-6-1, 1990
Kenilworth, NJ 07033
Tel: (908) 298-5068
Fax: (908) 298-5388

Respectfully submitted,




Palaiyur S. Kalyanaraman
Attorney for Applicants
Reg. No. 34,634

I hereby certify that this correspondence
is being deposited with the U.S. Postal
Service as First Class Mail in an envelope
addressed to Assistant Commissioner for
Patents, Washington, D.C. 20231 on


December 19, 2001

Palaiyur S. Kalyanaraman
Registered Representative



12/19/2001

Signature and Date of Signature



IDS/#5
1/8/02/53

PATENT CASE IN01158K

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

A. Saksena *et al.*

Serial No.: 09/909,012

Filed: July 19, 2001

)
) Examiner: Not assigned yet
)
) Group Art Unit: Not assigned yet
)
)
) Atty. Docket No.: IN01158K

For: **NOVEL PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF
HEPATITIS C VIRUS**

RECEIVED

JAN 07 2002

Assistant Commissioner for Patents
Washington, D.C. 20231

TECH CENTER 1600/2900

INFORMATION DISCLOSURE STATEMENT

Sir:

It is requested that the following documents cited in the application, as listed below and in the accompanying form PTO-1449, be considered and made of record.

Documents cited in the Application:

U.S. 5,712,145
WO 89/04669
WO 98/17679
WO 98/22496
WO 99/07734
WO 00/09558
WO 00/09543
EP 381 216

Publications:

Pizzi *et al.* (1994) *Proc. Natl. Acad. Sci (USA)* 91:888-892
Failla *et al.* (1996) *Folding & Design* 1:35-42
Kollykhalov *et al.* (1994) *J. Virol.* 68:7525-7533
Komoda *et al.* (1994) *J. Virol.* 68:7351-7357
Landro *et al.* (1997) *Biochem.* 36:9340-9348
Ingallinella *et al.* (1998) *Biochem.* 37:8906-8914
Llinàs-Brunet *et al.* (1998) *Bioorg. Med. Chem. Lett.* 8:1713-1718
Martin *et al.* (1998) *Biochem.* 37:11459-11468
Dimasi *et al.* (1997) *J. Virol.* 71:7461-7469
Martin *et al.* (1997) *Protein Eng.* 10:607-614
Elzouki *et al.* (1997) *J. Hepat.* 27:42-48
BioWorld Today 9(217): 4 (November 10, 1998)
Berenguer *et al.* (1998) *Proc. Assoc. Am. Physicians* 110(2):98-112
Hoofnagle *et al.* (1997) *N. Engl. J. Med.* 336:347
R. Zhang *et al.*, *Analytical Biochemistry*, 270 (1999) 268-275


D. L. Sali *et al*, *Biochemistry*, 37 (1998) 3392-3401
K. Barlos *et al*, *Int. J. Pept. Protein Res.*, 37 (1991), 513-520
K. Holmberg *et al*, *Acta Chem. Scand.*, B33 (1979) 410-412
A. Marchetti *et al*, *Synlett.*, S1 (1999) 1000-1002
W. Han *et al*, *Bioorganic & Biomedical Chem Lett.*, 10 (2000) 711-713
S. Agrawal *et al*, "Development and Characterization of Hepatitis C Virus Serine
Protease Cell-based Trans-Cleavage Assay", *Hepatology* Supplement to Volume 30 (No. 4,
Part 2, October 1999), *Abstract No. 615* (Proceedings of AASLD 50th Annual Meeting,
Dallas, Texas, November 5-9, 1999).
L. Hughes, *Org. Reactions*, 42 (1992) 335.
R. F. Heck, *Org. Reactions*, 27 (1989) 345-390.

The submission of these documents is not to be presumed as an admission that these documents are prior art. The documents are being furnished solely for their possible utility in the examination of the present case. Since no Office Action has issued on the merits of this case, Applicants believe that no fee is due at this time. If, however, any fees are due, the Office may charge such fees to Deposit Account No. 19-0365.

If the Examiner has any questions, the Examiner is invited to contact the undersigned.

December 19, 2001
Schering-Plough Corporation
2000 Galloping Hill Road
Patent Department, K-6-1, 1990
Kenilworth, NJ 07033
Tel: (908) 298-5068
Fax: (908) 298-5388


Respectfully submitted,



Palaiyur S. Kalyanaraman
Attorney for Applicants
Reg. No. 34,634

I hereby certify that this correspondence
is being deposited with the U.S. Postal
Service as First Class Mail in an envelope
addressed to Assistant Commissioner for
Patents, Washington, D.C. 20231 on

December 20, 2001

Palaiyur S. Kalyanaraman
Registered Representative

 12/20/01
Signature and Date of Signature

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE
FORM PTO-1449
INFORMATION DISCLOSURE STATEMENT
BY APPLICANTATTY. DOCKET NO.:
IN01158KSERIAL NO.:
09/909,012APPLICANT:
SAKSENA, et alFILING DATE:
July 19, 2001GROUP:
To Be Assigned

(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
AA	U.S. 5,712,145					
AB						

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
AC	WO 89/04669					
AD	WO 98/17679					
AE	WO 98/22496					
AF	WO 98/07734					
AG	WO 00/09558					
AH	WO 00/09543					
AI	EP 381 216					
AJ						
AK						

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

AL	Pizzi, (1994) <i>Proc. Natl. Acad. Sci(USA)</i> 91:888-892
AM	Failla (1996) <i>folding & Design</i> 1:35-42
AN	Kollykhalov (1994) <i>J. Virol.</i> 68:7525-7533
AO	Komoda (1994) <i>J. Virol.</i> 68:7351-7357
AP	Landro (1997) <i>Biochem</i> 36:9340-9348
AQ	Ingallinella (1998) <i>Biochem</i> 37:8906-8914
AR	Llinas-Brunet (1998) <i>Bioorg. Med. Chem. Lett.</i> 8:1713-1718
AS	Martin (1998) <i>Biochem</i> 37:11459-11468
AT	Dimasi (1997) <i>J. Virol.</i> 71:7461-7469
AU	Martin (1997) <i>Protein Eng.</i> 10:607-614
AV	Elzouki (1997) <i>J. Hepat.</i> 27:42-48
AW	<i>Bio World Today</i> 9(217): 4 (November 10, 1998)
AX	Berenguer (1998) <i>Proc. Assoc. Am. Physicians</i> 110(2): 98-112
AY	Hoofnagle (1997) <i>New England Journal Med.</i> 336:347
AZ	Zhang (199) <i>Analytical Biochemistry</i> 270:268-275
BA	Sali (1998) <i>Biochemistry</i> 3392-3401
BB	Barlos (1991) <i>Int. J. Pept. Protein Res</i> 513-520
BC	Holmberg (1979) <i>Acta Chem. Scand.</i> , B33:410-412
BD	Agrawal(1999) <i>Hepatology Supplement to Vol 30</i> "Development and Characterization of Hepatitis C Virus Serine Protease Cell-based Trans-Cleavage Assay"
BE	Hughes (1992) <i>Org. Reactions</i> 42:335
BF	Heck (1989) <i>Org. Reactions</i> 27:345-390
BG	Han, (2000) <i>Bioorganic & Medicinal Chemistry Letters</i> 10 "α-Ketoamides, α-Ketoesters and α-Kiketones as HCV NS3 Protease Inhibitors" pp. 711-713.
BH	Marchetti(1999) <i>Synlett</i> , Vol. S1, "Synthesis of Two Novel Cyclic Biphenyl Ether Analogs of an Inhibitor of HCV NS3 Protease", pp 1000-1002.

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

RECEIVED

JAN 07 2002

1690/2900